Authors

Latest:

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

Mark D. Pegram, MD, Stanford Cancer Center

Latest:

Expanding Treatment Options for HER2+ Breast Cancer

Mark R. Gilbert, MD

Latest:

Dr. Gilbert on Precision Medicine in Glioblastoma

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Mark R. Litzow, MD

Latest:

Dr. Litzow on New Immunologic Therapies in ALL

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Mark R. Litzow, MD, Mayo Clinic

Mark R. Litzow, MD, The Mayo Clinic

Mark S. Austenfeld, MD, Kansas City Urology Care

Mark S. Soberman, MD, MBA, FACS

Latest:

Dr. Soberman on Theme of Next-Generation Multidisciplinary Care for Patients With Cancer

Mark S. Soberman, MD, MBA, FACS, the 2017 to 2018 President of the Association of Community Cancer Centers (ACCC), discusses his presidential theme of next-generation multidisciplinary care for patients with cancer.

Mark S. Talamonti, MD

Latest:

Dr. Talamonti on Advantages with Minimally Invasive Surgery for Pancreatic Cancer

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the advantages of minimally invasive surgery for patients with pancreatic cancer.

Mark Scholz, MD

Latest:

Dr. Scholz on Significance of ARAMIS Trial in CRPC

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with metastatic castration-resistant prostate cancer.

Mark Schroeder, MD

Latest:

Dr. Schroeder on Tolerability of Treatment For Myeloma

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Mark Shapiro, MD, PhD

Latest:

Dr. Shapiro Discusses Bosutinib in CML

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Mark Sisco, MD

Latest:

Dr. Sisco Discusses Complications After Bilateral and Unilateral Mastectomies with Immediate Reconstruction

Mark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction

Mark Socinski, MD, University of Pittsburgh

Mark Stein, MD

Latest:

Dr. Stein on AR-Resistance in Prostate Cancer

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

Mark T. Fleming, MD

Latest:

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Mark W. Bustoros, MD

Latest:

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Mark W. Karwal, MD, University of Iowa Health Care

Mark W. Kieran, MD, PhD

Latest:

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

Marko Velimirovic, MD

Latest:

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.